PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that share its vision of building responsible supply chains, the Pharmaceutical Supply Chain Initiative (PSCI) has welcomed its first cohort of Supplier Partners: Delpharm, Samsung Biologics, and Suven.
Strengthening supplier collaboration
These partnerships signal a growing alignment within the industry to promote excellence in safety, environmental, and social outcomes. Delpharm, Samsung Biologics, and Suven bring significant expertise in contract development, biopharmaceutical services, and pharmaceutical manufacturing, respectively, contributing to global supply chain efficiency and sustainability. By joining the PSCI as Supplier Partners, they reinforce their dedication to not only delivering high-quality products but also fostering sustainable and responsible business operations, aligned with the PSCI Principles for Responsible Supply Chain Management.
Dr. Deirdre O'Reilly, Chair of the PSCI, emphasised the importance of this new model:
"By solidifying the PSCI’s partnerships with suppliers, we create a stronger collaboration that promotes responsible sourcing practices across the industry. This unified approach empowers suppliers to have a voice and be recognised for their commitment to ethical sourcing and contribute to the positive impacts of the PSCI."
Leading the way in pharmaceutical supply chains
Each of the new Supplier Partners brings a unique contribution to the pharmaceutical supply chain:
• Nicolas Ragot, Managing Director of Delpharm, noted, “As a major CDMO to the pharmaceutical industry, Delpharm is proud to join the PSCI community as an official Supplier Partner. Becoming a Supplier Partner demonstrates our commitment to driving excellence in safety, environmental, and social outcomes across the global pharmaceutical supply chain.”
• John Rim, CEO and President of Samsung Biologics, highlighted the company’s sustainability efforts:
"The PSCI’s Supplier Partnership is a strong reaffirmation of Samsung Biologics’ commitment to achieve net zero across the supply chain. We will integrate the PSCI Principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain."
• Metlapalli Srinivasu, Vice President Corp. Head of EHS & ESG at Suven Pharmaceuticals, said, “Being a Supplier Partner represents a significant milestone for Suven Pharma. It reinforces our role as a trusted partner in advancing global health and demonstrates our commitment to high-quality pharmaceutical solutions."
Collaboration for a sustainable future
The PSCI’s Supplier Partnership category was created in response to the growing interest from suppliers to be actively involved in PSCI activities and to recognise those that engage in responsible practices. Supplier Partners gain access to a shared platform for collaboration and performance improvement, allowing them to play an active role in advancing the industry’s goals of sustainability, ethical sourcing, and operational excellence.
For more information about Supplier Partnership, click here.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...